Hyundai Bioscience Co., Ltd.
KOSDAQTotal Valuation
Hyundai Bioscience Co., Ltd. carries a market capitalization of 715.09B, placing it among publicly traded companies globally. Its enterprise value stands at 1.26T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 715.09B |
| Enterprise Value | 1.26T |
Valuation Ratios
The price-to-sales ratio is 408.45, and the price-to-book ratio stands at 1,023.48.
| PE Ratio | N/A |
| PS Ratio | 408.45 |
| PB Ratio | 1,023.48 |
| P/TBV Ratio | 21.40 |
| P/FCF Ratio | -83.45 |
| P/OCF Ratio | -81.59 |
Enterprise Valuation
| EV / Sales | 401.20 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 93.15 |
Financial Position
Hyundai Bioscience Co., Ltd. maintains a current ratio of 2.40, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.48, indicating elevated leverage, while an interest coverage ratio of -12.81 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.40 |
| Quick Ratio | 2.27 |
| Debt / Equity | 13.48 |
| Debt / EBITDA | -1.10 |
| Interest Coverage | -12.81 |
Financial Efficiency
| Return on Equity (ROE) | -1,334.38 |
| Return on Assets (ROA) | -15.69 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.18 |
Taxes
| Income Tax | 2.94M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Hyundai Bioscience Co., Ltd.'s stock has gained approximately 38.63424% over the past 52 weeks. The 50-day moving average sits at 10,987.80, while the 200-day moving average is 9,218.48.
| Beta (5Y) | N/A |
| 52-Week Price Change | 38.63424% |
| 50-Day Moving Average | 10,987.80 |
| 200-Day Moving Average | 9,218.48 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Hyundai Bioscience Co., Ltd. generated 3.13B in revenue and converted that into -21.30B in net income, yielding earnings per share of -221.18. EBITDA reached -13.69B, while operating income came in at -13.69B.
| Revenue | 3.13B |
| Gross Profit | -17.32M |
| Operating Income | -13.69B |
| Pretax Income | -21.28B |
| Net Income | -21.30B |
| EBITDA | -13.69B |
| EBIT | -13.69B |
| Earnings Per Share (EPS) | -221.18 |
Balance Sheet
Hyundai Bioscience Co., Ltd. holds 37.80B in cash and equivalents against 15.09B in total debt, resulting in a net debt position of 6.56B. Total book value stands at 1.25B, with working capital of 23.34B providing operational flexibility.
| Cash & Cash Equivalents | 37.80B |
| Total Debt | 15.09B |
| Net Debt | 6.56B |
| Equity (Book Value) | 1.25B |
| Book Value Per Share | 12.99 |
| Working Capital | 23.34B |
Cash Flow
Hyundai Bioscience Co., Ltd. produced -15.69B in operating cash flow over the past twelve months. After subtracting -348.59M in capital expenditures, free cash flow totaled -16.03B - equivalent to -166.63 per share.
| Operating Cash Flow | -15.69B |
| Capital Expenditures | -348.59M |
| Free Cash Flow | -16.03B |
| FCF Per Share | -166.63 |
Margins
Hyundai Bioscience Co., Ltd. operates with a gross margin of -0.55, reflecting its pricing power and cost economics. The operating margin of -436.88 and net profit margin of -679.88 provide insight into operational efficiency.
| Gross Margin | -0.55 |
| Operating Margin | -436.88 |
| Pretax Margin | -679.15 |
| Profit Margin | -679.88 |
| EBITDA Margin | -436.88 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.38 |
| FCF Yield | -1.20 |
Stock Splits
Hyundai Bioscience Co., Ltd.'s most recent stock split took place on July 24, 2025 with a 1:2 split ratio.
| Last Split Date | 7/24/2025 |
| Split Ratio | 1:2 |
Scores
Hyundai Bioscience Co., Ltd. posts an Altman Z-Score of 43.80, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 43.80 |